Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Abstract
PMID
Authors J. Zhu Z. Song Y. Zhao J. Zhang Y. Li D. Li R. Schneider Y. Ding Z. Sun Y. Qin Z-W. Chang Z. Wang Z. Zhang P. Zhang Y. Wang J. Zhang
Title 45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors
URL https://www.esmoopen.com/article/S2059-7029(24)00042-5/fulltext
Abstract Text Background Aberrant activation of FGFR signaling promotes cancer cell proliferation and tumor growth. Targeting FGFR2/3 selectively may alleviate FGFR1-dependent hyperphosphatemia and could provide better efficacy. Here, we evaluated the safety and pharmacokinetics of a selective and potent FGFR2/3 inhibitor ABSK061 in advanced solid tumors in a phase 1 open-label study (NCT05244551). Methods As of November 2023, a total of 28 patients with advanced solid tumors were enrolled in the escalation part of the study. These patients were treated with ABSK061 twice daily (5mg-100mg BID) or once daily (150mg QD) in 28-day cycles. 75mg BID and 150mg QD were selected to explore the recommended doses for expansion. Results Among the 28 patients, the mean age was 53.5 years with 54% males. When comparing 150mg QD with 75mg BID, 150mg QD resulted in ∼50% higher Cmax,ss, ∼50% lower Ctrough,ss and similar AUC0-24h,ss. No dose-limiting toxicity was observed. The most common treatment-related adverse events (TRAEs) (≥15%) included alanine aminotransferase (ALT) increase, aspartate aminotransferase (AST) increase, and anaemia. Grade ≥3 TRAE was reported in 5 patients, including anaemia, ALT increase, AST increase, bilirubin conjugated increase, blood bilirubin increase, gamma-glutamyltransferase increase, and pulmonary embolism. Hyperphosphatemia was reported in only 11% (3/28) of patients, and all were grade 1. One patient on 75mg BID experienced pulmonary embolism with a prior history, discerned as an unlikely related serious adverse event (SAE) by the investigators. Among the 5 patients with prior treatments and FGFR2 fusion/amplification or FGFR3 fusion, 2 achieved partial response (PR) and 2 achieved stable disease (SD). Objective response rate was 40%. All 4 patients are continuing treatment. Disease control rate was 80%. PR was observed in non-small cell lung cancer (FGFR2 fusion) and urothelial carcinoma (FGFR3 fusion). Conclusions This study demonstrated the anti-tumor activity of ABSK061 in patients with FGFR2/3 alterations and its favorable safety profile, which warrants further investigation.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
ABSK061 ABSK061 2 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
ABSK061 ABSK-061|ABSK 061 FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 ABSK061 inhibits FGFR2 and FGFR3, potentially leading to antitumor activity (ESMO Open 9 (2024): 102274).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 fusion lung non-small cell carcinoma predicted - sensitive ABSK061 Case Reports/Case Series Actionable In a Phase I trial, ABSK061 treatment resulted in a partial response in a patient with non-small cell lung cancer harboring an FGFR2 fusion (ESMO Open 9 (2024): 102274); NCT05244551). detail...
FGFR3 fusion transitional cell carcinoma predicted - sensitive ABSK061 Case Reports/Case Series Actionable In a Phase I trial, ABSK061 treatment resulted in a partial response in a patient with urothelial carcinoma harboring an FGFR3 fusion (ESMO Open 9 (2024): 102274); NCT05244551). detail...